$46.5+ Billion Gene Therapy Market to Grow at 22.8% CAGR, Globally, by 2030 | Harnessing the Power of Gene Editing

The increasing number of approvals of gene therapies within North America and Europe are the major reasons for market growth.

Gene Editing Market

PORTLAND, OREGON, UNITED STATES, March 13, 2024 /EINPresswire.com/ -- [illegible]

Allied Market Research published a report, titled, "[Gene Therapy Market](#) by Vector Type (Viral Vector, Non-Viral Vector), by Therapy (In Vivo Therapy, Ex Vivo Therapy), by Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth factors, Receptors, Others), by Application (Oncological Disorders, Rare Diseases, Neurological Disorders, Other Diseases): Global Opportunity Analysis and Industry Forecast, 2020-2030." According to the report, the global Gene Therapy Market Size was Valued at USD 6.0 billion in 2020 and is Projected to Garner USD 46.5 billion by 2030, registering a CAGR of 22.8% from 2021 to 2030.

The gene therapy market refers to the pharmaceutical and biotechnology industry segment focused on the development, production, and commercialization of gene therapy products and treatments. Gene therapy involves the introduction, removal, or modification of genetic material within an individual's cells to treat or prevent diseases.

[illegible]:
https://www.alliedmarketresearch.com/request-sample/2841

□□□□'□ □ □□□□□□□□□□ □□ □□□ □□□□□□□ □□ □□□ □□□□ □□□□□□□ □□□□□□:

□Technology and Approaches: Gene therapy employs various technologies and approaches to target genetic abnormalities underlying diseases. This includes gene addition (introducing a functional gene into cells), gene editing (modifying existing genes within cells), and gene silencing (suppressing the expression of disease-causing genes). Technologies such as CRISPR-Cas9, viral vectors (e.g., adenoviruses, lentiviruses), and non-viral vectors are commonly used in gene therapy research and development.
□Therapeutic Areas: Gene therapy holds promise for treating a wide range of diseases, including genetic disorders (e.g., cystic fibrosis, muscular dystrophy), rare diseases, cancer, cardiovascular diseases, neurological disorders, and infectious diseases. Advances in gene therapy research have expanded its potential applications across diverse therapeutic areas.
□Market Growth Drivers: The gene therapy market has witnessed significant growth in recent years, driven by factors such as advancements in gene editing technologies, increasing investment in research and development, growing understanding of the genetic basis of diseases, and regulatory approvals for gene therapy products. Additionally, the emergence of personalized medicine and precision therapies has spurred interest in gene therapy approaches tailored to individual patients.
□Clinical Successes and Challenges: Several gene therapy products have demonstrated clinical success and received regulatory approval in recent years, including treatments for spinal muscular atrophy, inherited retinal diseases, and certain types of cancer. However, the field also faces challenges such as safety concerns, immune responses to viral vectors, manufacturing complexities, and high treatment costs. Overcoming these challenges is crucial for the continued growth and adoption of gene therapy treatments.
□Regulatory Environment: Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play a key role in overseeing the development and approval of gene therapy products. Regulatory pathways for gene therapy products may differ from those of traditional pharmaceuticals due to the unique nature of gene-based treatments, requiring innovative approaches to safety and efficacy assessment.
□Market Landscape and Players: The gene therapy market encompasses a diverse array of stakeholders, including pharmaceutical companies, biotechnology firms, academic research institutions, contract manufacturing organizations (CMOs), and regulatory bodies. Market players may collaborate on research partnerships, licensing agreements, and commercialization efforts to advance gene therapy development and bring innovative treatments to market.

□□□ □□□□ □□□□□□□ □□□□□□□□□□:

- Gilead Sciences
- Orchard Therapeutics.
- Bristol-Myers Squibb.
- Therapeutics plc
- Adverum Biotechnologies, Inc.
- Amgen Inc.

- Jazz Pharmaceuticals,
- Shenzhen SiBiono Genentech
- Adaptimmune
- Novartis AG
- Shanghai Sunway Biotech Co., Ltd.

□□□□ □□□□□□□ □□□□□□ □□□□□□□□□□□□ □□□ □□ □□□□ □□□□□ □□ □□□□□□□ □□□□□□□, □□□□□□□□□□:

On the basis of gene type, the antigen segment accounted for the highest market share in 2020, generating nearly one-fourth of the global gene therapy market. Rise in the prevalence of diseases such as autoimmune diseases & cancer and increase in R&D activities associated with antigen-based gene therapies propel the growth of the segment. The deficiency segment, however, is anticipated to cite the fastest CAGR of 26.0% from 2021 to 2030.

On the basis of application, the oncological disorders segment generated the highest share in 2020, holding more than two-fifths of the global gene therapy market. The same segment is also expected to cite the fastest CAGR of 23.5% from 2021 to 2030. Increase in the prevalence of cancer and availability of diverse gene therapy products that can be used to treat cancer fuel the segment growth.

On the basis of region, North America contributed to the major market share in terms of revenue 2020, holding nearly half of the global gene therapy market. The Asia-Pacific region, simultaneously, is projected to cite the fastest CAGR of 25.4% from 2021 to 2030. This is attributed to the facts such as rise in the prevalence of chronic diseases, increase in healthcare expenditure, developments in healthcare infrastructure, availability of reimbursements, and the presence of major market players in the province.

□□□□□□□□ □□□ □□□□□□: https://www.alliedmarketresearch.com/purchase-enquiry/2841

□□□ □□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□ □□□ □□□□□□ □□ □□□□□ □□□□□□□□□□ □□□□□□□□:

- Which are the driving factors responsible for the growth of market?
- Which are the roadblock factors of this market?
- What are the new opportunities, by which market will grow in coming years?
- What are the trends of this market?
- Which are main factors responsible for new product launch?
- How big is the global & regional market in terms of revenue, sales and production?
- How far will the market grow in forecast period in terms of revenue, sales and production?
- Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
- How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
- Which region has more opportunities?

By Region Outlook

• North America
(U.S., Canada, Mexico)
• Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
• LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

□□□□□□□□ □□□□□□□□:

David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com

□□□□□ □□

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Market Research
+1 5038946022
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn